CN1894250B - 取代的8-杂芳基黄嘌呤 - Google Patents

取代的8-杂芳基黄嘌呤 Download PDF

Info

Publication number
CN1894250B
CN1894250B CN2004800314554A CN200480031455A CN1894250B CN 1894250 B CN1894250 B CN 1894250B CN 2004800314554 A CN2004800314554 A CN 2004800314554A CN 200480031455 A CN200480031455 A CN 200480031455A CN 1894250 B CN1894250 B CN 1894250B
Authority
CN
China
Prior art keywords
pyridyl
xanthine
dipropyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800314554A
Other languages
English (en)
Chinese (zh)
Other versions
CN1894250A (zh
Inventor
G·王
J·M·里格尔
R·D·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erjian Sales Co ltd
Original Assignee
Adenosine Therapeutics LLC
PGxHealth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adenosine Therapeutics LLC, PGxHealth LLC filed Critical Adenosine Therapeutics LLC
Publication of CN1894250A publication Critical patent/CN1894250A/zh
Application granted granted Critical
Publication of CN1894250B publication Critical patent/CN1894250B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2004800314554A 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤 Expired - Fee Related CN1894250B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49787503P 2003-08-25 2003-08-25
US60/497,875 2003-08-25
PCT/US2004/027133 WO2005021548A2 (en) 2003-08-25 2004-08-20 Substituted 8-heteroaryl xanthines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101556967A Division CN101851238B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤

Publications (2)

Publication Number Publication Date
CN1894250A CN1894250A (zh) 2007-01-10
CN1894250B true CN1894250B (zh) 2010-06-09

Family

ID=34272616

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800314554A Expired - Fee Related CN1894250B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤
CN2010101556967A Expired - Fee Related CN101851238B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010101556967A Expired - Fee Related CN101851238B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤

Country Status (19)

Country Link
US (3) US7342006B2 (cg-RX-API-DMAC10.html)
EP (2) EP1658291B1 (cg-RX-API-DMAC10.html)
JP (1) JP4769721B2 (cg-RX-API-DMAC10.html)
KR (1) KR101222364B1 (cg-RX-API-DMAC10.html)
CN (2) CN1894250B (cg-RX-API-DMAC10.html)
AR (1) AR045499A1 (cg-RX-API-DMAC10.html)
AU (1) AU2004268964B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0413922B8 (cg-RX-API-DMAC10.html)
CA (1) CA2536553C (cg-RX-API-DMAC10.html)
DK (2) DK1658291T3 (cg-RX-API-DMAC10.html)
ES (2) ES2557310T3 (cg-RX-API-DMAC10.html)
IL (1) IL173723A (cg-RX-API-DMAC10.html)
NZ (1) NZ545715A (cg-RX-API-DMAC10.html)
PL (1) PL1658291T3 (cg-RX-API-DMAC10.html)
PT (1) PT1658291E (cg-RX-API-DMAC10.html)
RU (1) RU2357969C2 (cg-RX-API-DMAC10.html)
TW (1) TWI362390B (cg-RX-API-DMAC10.html)
WO (1) WO2005021548A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200602333B (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) * 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US7342006B2 (en) * 2003-08-25 2008-03-11 Adenosine Therapeutics, Llc Substituted 8-heteroaryl xanthines
EP1778712B1 (en) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CA2580860A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US7566401B2 (en) 2005-10-03 2009-07-28 Kelm Mark A Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
CN101466382A (zh) 2006-06-16 2009-06-24 PGx健康有限责任公司 取代的8-[6-氨基-3-吡啶基]黄嘌呤
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) * 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
US20110118276A1 (en) * 2008-07-16 2011-05-19 Edward Leung Methods of treating atherosclerosis
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
RU2404181C1 (ru) * 2009-06-02 2010-11-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) 3-метил-8-пиперазино-7-(тиетанил-3)-1-этилксантина гидрохлорид, проявляющий антиагрегационную и дезагрегационную активность
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
EP2499142B1 (en) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
US8940751B2 (en) 2010-09-13 2015-01-27 Advinus Therapeutics Private Limited Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
EP2465859A1 (en) * 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
CN102532137B (zh) * 2011-12-05 2014-12-10 辽宁医学院 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP4126866A1 (en) * 2020-03-26 2023-02-08 Inspyr Therapeutics, Inc. 8-substituted diaryl xanthines as dual a2a-a2b antagonists
JP2024521704A (ja) 2021-05-18 2024-06-04 アドベイト，エルエルシー Ａ２ｂアンタゴニストとしての環状アミド含有ピリジルキサンチン
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
WO2024050825A1 (en) * 2022-09-09 2024-03-14 National Institute Of Biological Sciences, Beijing Compounds as mlkl inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042214A2 (en) * 2001-11-09 2003-05-22 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
WO2003063800A2 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
AU1507099A (en) * 1997-12-15 1999-07-05 Kyowa Hakko Kogyo Co. Ltd. Preventives/remedies for sleep disturbance
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
ATE319452T1 (de) * 1999-10-29 2006-03-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen essstörungen
CN1420775A (zh) * 2000-02-17 2003-05-28 Cv治疗公司 鉴定及使用a2b腺苷受体拮抗剂介导哺乳动物细胞增殖的方法
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) * 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
US7342006B2 (en) 2003-08-25 2008-03-11 Adenosine Therapeutics, Llc Substituted 8-heteroaryl xanthines
US20060058322A1 (en) 2004-09-01 2006-03-16 Dewan Zeng Method of wound healing using A2B adenosine receptor antagonists
NZ554485A (en) * 2004-10-15 2010-12-24 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
KR101428113B1 (ko) * 2006-03-17 2014-08-07 길리애드 사이언시즈, 인코포레이티드 Ａ2ｂ 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042214A2 (en) * 2001-11-09 2003-05-22 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
WO2003063800A2 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Also Published As

Publication number Publication date
DK1658291T3 (da) 2013-10-28
PT1658291E (pt) 2013-10-21
US20080200456A1 (en) 2008-08-21
ES2440467T3 (es) 2014-01-29
TW200524931A (en) 2005-08-01
IL173723A (en) 2015-01-29
ZA200602333B (en) 2007-04-25
KR20060132549A (ko) 2006-12-21
JP4769721B2 (ja) 2011-09-07
EP2295434A3 (en) 2011-07-27
ES2557310T3 (es) 2016-01-25
BRPI0413922A (pt) 2006-10-24
AU2004268964B2 (en) 2010-03-11
WO2005021548A2 (en) 2005-03-10
TWI362390B (en) 2012-04-21
BRPI0413922B1 (pt) 2018-08-28
US20050065341A1 (en) 2005-03-24
DK2295434T3 (en) 2015-12-14
NZ545715A (en) 2009-02-28
RU2357969C2 (ru) 2009-06-10
BRPI0413922B8 (pt) 2021-05-25
EP1658291A2 (en) 2006-05-24
EP2295434A2 (en) 2011-03-16
CN101851238B (zh) 2012-07-18
US7732455B2 (en) 2010-06-08
JP2007503443A (ja) 2007-02-22
IL173723A0 (en) 2006-07-05
HK1148518A1 (en) 2011-09-09
HK1096397A1 (en) 2007-06-01
CN101851238A (zh) 2010-10-06
WO2005021548A3 (en) 2005-06-30
US7342006B2 (en) 2008-03-11
CN1894250A (zh) 2007-01-10
US20100273780A1 (en) 2010-10-28
EP2295434B1 (en) 2015-09-30
KR101222364B1 (ko) 2013-01-15
CA2536553C (en) 2013-01-29
PL1658291T3 (pl) 2014-03-31
CA2536553A1 (en) 2005-03-10
EP1658291B1 (en) 2013-10-02
AU2004268964A1 (en) 2005-03-10
RU2006109474A (ru) 2007-10-10
AR045499A1 (es) 2005-11-02

Similar Documents

Publication Publication Date Title
CN1894250B (zh) 取代的8-杂芳基黄嘌呤
US7579348B2 (en) Derivatives of 8-substituted xanthines
US7601723B2 (en) Pyridyl substituted xanthines
US20100120765A1 (en) Pyrazolyl substituted xanthines
US7875608B2 (en) Substituted 8-[6-amino-3pyridyl]xanthines
JP5417558B2 (ja) 置換８−［６−アミノ−３−ピリジル］キサンチン類
CN101466382A (zh) 取代的8-[6-氨基-3-吡啶基]黄嘌呤
HK1096397B (en) Substituted 8-heteroaryl xanthines
HK1148518B (en) Substituted 8-heteroaryl xanthines
MXPA06002223A (en) Substituted 8-heteroaryl xanthines
HK1131569A (en) Substituted 8-[6-amino-3-pyridyl]xanthines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096397

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090213

Address after: Massachusetts

Applicant after: PGXHEALTH, LLC

Address before: Virginia

Applicant before: ADENOSINE THERAPEUTICS, LLC

ASS Succession or assignment of patent right

Owner name: PGX HEALTHY CO.,LTD.

Free format text: FORMER OWNER: ALBERT CO., LTD.

Effective date: 20090213

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1096397

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: ZHUOWEISI PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: PGX HEALTH LLC

CP03 Change of name, title or address

Address after: Massachusetts, USA

Patentee after: Zhuowei Pharmaceutical Co.,Ltd.

Address before: Massachusetts

Patentee before: PGXHEALTH, LLC

ASS Succession or assignment of patent right

Owner name: DOUG WOOD MEDICINE CORP.

Free format text: FORMER OWNER: CLINICAL DATA INC.

Effective date: 20131023

Owner name: CLINICAL DATA INC.

Free format text: FORMER OWNER: TROVIS PHARMACEUTICALS LLC

Effective date: 20131023

Owner name: TROVIS PHARMACEUTICALS LLC

Free format text: FORMER OWNER: ZHUOWEISI PHARMACEUTICAL CO., LTD.

Effective date: 20131023

Owner name: DOUG WOOD MEDICINE CORP.

Free format text: FORMER OWNER: FURUISITE LABORATORY HOLDING CO., LTD.

Effective date: 20131023

Owner name: FURUISITE LABORATORY HOLDING CO., LTD.

Free format text: FORMER OWNER: DOUG WOOD MEDICINE CORP.

Effective date: 20131023

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20131023

Address after: Bermuda Hamill

Patentee after: Laboratory of Forest Holdings Ltd.

Address before: Virginia

Patentee before: Dogwood Pharmaceuticals, Inc.

Effective date of registration: 20131023

Address after: Virginia

Patentee after: Dogwood Pharmaceuticals, Inc.

Address before: American New York

Patentee before: Clinical Data Inc.

Effective date of registration: 20131023

Address after: American New York

Patentee after: Clinical Data Inc.

Address before: American New York

Patentee before: Travis Pharmaceutical Holdings

Effective date of registration: 20131023

Address after: American New York

Patentee after: Travis Pharmaceutical Holdings

Address before: Massachusetts, USA

Patentee before: Zhuowei Pharmaceutical Co.,Ltd.

Effective date of registration: 20131023

Address after: Virginia

Patentee after: Dogwood Pharmaceuticals, Inc.

Address before: Bermuda Hamill

Patentee before: Laboratory of Forest Holdings Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210729

Address after: New jersey, USA

Patentee after: Erjian Sales Co.,Ltd.

Address before: Virginia

Patentee before: Dogwood Pharmaceuticals, Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100609